文献速递胰腺与胆道疾病消化内镜

内镜逆行胰胆管造影术相关不良事件:系统评价与荟萃分析

Adverse Events Associated With Endoscopic Retrograde Cholangiopancreatography: Systematic Review and Meta-Analysis.
PubMed 文献 · Gastroenterology · 2024-11-07

该系统评价与荟萃分析纳入2000年后至2024年3月12日报告的380项研究,评估内镜逆行胰胆管造影术(ERCP)相关不良事件的发生率。结果显示全因死亡率为0.2%,胰腺炎总体发生率为4.6%,首次患者为6.5%,且2000至2023年间胰腺炎发生率保持稳定。

要点

  • ERCP相关全因死亡率为0.2%(95%CI 0.1%-0.3%)。
  • 全因胰腺炎发生率为4.6%,首次患者为6.5%。
  • 2000至2023年胰腺炎发生率保持稳定(平均年度变化百分比0.06)。

核心结论

  • ERCP相关不良事件仍常见,尽管技术、预防和识别有所改进,ERCP后胰腺炎发生率保持稳定。

研究设计与样本

  • 系统评价与荟萃分析,纳入2000年后至2024年3月12日报告ERCP不良事件的研究,共380项。
  • 采用DerSimonian and Laird随机效应模型计算不良事件发生率,并进行亚组、配对荟萃分析和meta回归。

主要发现

  • 全因中归因于ERCP的死亡率为0.2%(95%CI 0.1%-0.3%;I²=44%;n=47,258)。
  • 全因中胰腺炎总体发生率为4.6%(95%CI 4.0%-5.1%;I²=96%;n=293,378),首次患者为6.5%(95%CI 5.9%-7.1%;I²=89%;n=88,809)。
  • 2000至2023年间胰腺炎发生率保持稳定(平均年度变化百分比0.06,95%CI -0.27至0.39)。
  • 全因中出血发生率为1.5%(95%CI 1.2%-1.7%;I²=93%;n=229,655),胆管炎为2.5%(95%CI 1.9%-3.3%;I²=96%;n=121,619),胆囊炎为0.8%(95%CI 0.5%-1.2%;I²=39%;n=7,799),穿孔为0.5%(95%CI 0.4%-0.6%;I²=90%;n=306,378)。

临床怎么用

  • 作者认为这些结果对患者、内镜医师和政策制定者很重要,可用于知情同意并鼓励实施可用的风险缓解策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Endoscopic retrograde cholangiopancreatography (ERCP)-related adverse events (AEs) are associated with morbidity, mortality, and health care expenditure. We aimed to assess incidences and comparisons of ERCP AEs. METHODS: We included studies performed after 2000 reporting on ERCP AEs from database inception through March 12, 2024. Outcomes included pancreatitis, bleeding, cholangitis, cholecystitis, perforation, and death. DerSimonian and Laird random effects meta-analyses were performed to calculate incidences of AEs. Subgroup and pairwise meta-analyses were performed. Meta-regression was performed on median recruitment year to assess temporal trends in pancreatitis incidence. RESULTS: A total of 380 studies were included. The incidence of death attributable to ERCP was 0.2% (95% confidence interval [CI], 0.1%-0.3%; I2, 44%; n = 47,258) in all-comers. The overall incidence of pancreatitis was 4.6% (95% CI, 4.0%-5.1%; I2, 96%; n = 293,378) among all-comers and 6.5% (95% CI, 5.9%-7.1%, I2, 89%; n = 88,809) among first-time patients. Pancreatitis incidence remained stable between 2000 and 2023 (average annual percent change 0.06, 95% CI, -0.27 to 0.39). The overall incidences of the following AEs for all-comers were: bleeding (1.5%; 95% CI, 1.2%-1.7%; I2, 93%; n = 229,655), cholangitis (2.5%; 95% CI, 1.9%-3.3%; I2, 96%; n = 121,619), cholecystitis (0.8%; 95% CI, 0.5%-1.2%; I2, 39%; n = 7799), and perforation (0.5%; 95% CI, 0.4%-0.6%; I2, 90%; n = 306,378). CONCLUSIONS: ERCP-associated AEs remain common. Incidence of post-ERCP pancreatitis remained static despite improvements in techniques, prevention, and recognition. These results are important to patients, endoscopists, and policy makers to inform consent and to encourage implementation of available risk mitigation strategies.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Bishay K, Meng ZW, Khan R, et al. Adverse Events Associated With Endoscopic Retrograde Cholangiopancreatography: Systematic Review and Meta-Analysis. Gastroenterology. 2024. PMID: 39515394. doi:10.1053/j.gastro.2024.10.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。